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Abstract
Background: New sources for discovering novel antiviral agents are desperately needed. The current antiviral
products are both expensive and not very effective.
Methods: The antiviral activity of methanol extract of mung bean sprouts (MBS), compared to Ribavarin and
Acyclovir, on respiratory syncytial virus (RSV) and Herpes Simplex virus −1 (HSV-1) was investigated using
cytotoxicity, virus yield reduction, virucidal activity, and prophylactic activity assays on Vero and MRC-5 cell lines.
Moreover, the level of antiviral cytokines, IFNβ, TNFα, IL-1, and IL-6 was assessed in MBS-treated, virally infected,
virally infected MBS-treated, and control groups of MRC-5 cells using ELISA.
Results: MBS extract showed reduction factors (RF) 2.2 × 10 and 0.5 × 102 for RSV and HSV-1, respectively. The 2 h
incubation virucidal and prophylactic selectivity indices (SI) of MBS on RSV were 14.18 and 12.82 versus Ribavarin SI
of 23.39 and 21.95, respectively, and on HSV-1, SI were 18.23 and 10.9 versus Acyclovir, 22.56 and 15.04, respectively.
All SI values were >10 indicating that MBS has a good direct antiviral and prophylactic activities on both RSV and
HSV-1. Moreover, interestingly, MBS extract induced vigorously IFNβ, TNFα, IL-1, and IL-6 cytokines in MRC-5
infected-treated group far more than other groups (P < 0.05) and induced TNFα and IL-6 in treated group more
than infected group (P < 0.05).
Conclusions: MBS extract has potent antiviral and to a lesser extent, prophylactic activities against both RSV and
HSV-1, and in case of HSV-1, these activities were comparable to Acyclovir. Part of the underlying mechanism(s) of
these activities is attributed to MBS potential to remarkably induce antiviral cytokines in human cells. Hence, we
infer that MBS methanol extract could be used as such or as purified active component in protecting and treating
RSV and HSV-1 infections. More studies are needed to pinpoint the exact active components responsible for the
MBS antiviral activities.
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Background
During the past decade, many potent agents have be-
come available against viral infections; however, the
increasing clinical use or the abuse of these agents has
been associated with the emergence of dangerous drug-
resistant viral strains. In addition, the dose-limiting toxic
effects of the known antiviral agents have been observed
among patients especially immunocompromised individ-
uals [1–3].
Plant bioactive molecules which occur in plants as sec-
ondary metabolites have significant defense mechanisms
against predation, herbivores, fungal attack, microbial
invasion, and viral infections [4]. Therefore, during the
recent decade, extracts of plants as phytochemicals, such
as phenolic compounds derived from the secondary
plant metabolism, are getting more important as potential
sources for viral inhibitors. Many studies showed a great
range of pharmacological effects of these substances, in-
cluding vasodilatation, antiallergenic, anti-inflammatory
and antiviral properties [5]. More to the point, the relative
success of various species of medicinal plant extracts with
antiviral properties has raised optimism about the future
of phyto-antiviral agents [6].
The discovery of safe and effective antiviral agents
from plant extracts may secure humanity from the
drug resistant viruses. Therefore, in order to discover
new sources of safe antiviral therapies, the objectives
of the current study are to investigate whether there
is any antiviral activity of mung bean sprout (Vigna
radiata L.), or (MBS), methanol crude extract and to
assess part of the underlying mechanism of action of
the antiviral activity, if any, of this methanol crude
extract. Discovering effective antiviral plant extract is
important in breaking the long-lasting shortage of
antiviral drugs in industry and to boost the safety use
of antiviral agents. MBS antiviral activity can be used
in the form of extract or by isolating the responsible
active component(s).
Results
To investigate the in vitro antiviral properties of MBS
extract, four approaches were performed. These methods
included end point titration technique (EPTT), plaque
assay, cytopathic reduction assay, and microculture tetra-
zolium assay (MTT).
Estimating the antiviral activity by virus yield reduction
assay
It has been shown that the virus yield reduction assay is
a powerful technique for evaluating the efficacy of
potential antiviral compounds [7]. In order to assess the
antiviral activity, the maximum nontoxic dose of MBS
extract, i.e., IC50 was applied to virus host cells after
infection with certain virus in an attempt to measure the
reduction of virus titer. The reductions of virus titers
(RSV and HSV-1) were determined in term of virus titer
log after treatment in addition to the reduction factor
(RF), i.e. the ratio of the virus titer in the absence of the
extract over virus titer in the presence of the extract [8].
In this study, MBS extract showed moderate antiviral
activity on HSV-1 titration in which HSV-1 titer was
reduced by two log (Table 1). On the other hand, MBS
extract showed slight antiviral activity against RSV as RSV
virus titer was reduced by one log (Table 1). MBS extract
showed RF values of ≥ 10 indicating a pronounced anti-
viral activities.
The virucidal, or Direct Virus Inactivation (DVI) and the
prophylactic, or Inhibition of Virus Replication (IVR) by
MBS extract
The neutralization and the inhibitory effects of MBS ex-
tract on virus replication (RSV and HSV-1) were studied.
The study included incubation of the extract with virus
specific cells (Vero and MRC-5) or with the virus itself.
The results were obtained by microscopic examination for
virus-induced CPE and the measurement of optical dens-
ity by the MTT assay. The results of cytopathic reduction
assay were expressed as mean of three independent exper-
iments with five extract concentrations. As demonstrated
in (Table 2), only the first concentration (220.96 mg/ml)
of MBS extract inhibited the RSV-induced CPE com-
pletely at different incubation times while 25 % CPE
started to develop at the concentration of 110.48 mg/ml
when the virus was mixed with MBS extract and was then
applied directly to Vero cells (zero hour time of incuba-
tion). The reduction of 50 % RSV-CPE was observed when
the virus was incubated for zero hour with 55.24 mg/ml of
MBS and for 1 h and 2 h with 27.62 mg/ml of MBS ex-
tract. On the other hand, when the extract was incubated
for 30 min and 1 h with cells before virus infection
55.24 mg/ml of MBS extract produced 25 % of RSV-CPE
Table 1 The reduction in the RSV and HSV-1 titers after MBS extract treatment. The virus titer was obtained by EPTT to determine
the virus titer in (TCID50/ml)
Virus Virus titer before treatment Virus titer after treatment aVirus titer reduction bReduction factor
RSV 3.16 × 10−3 1.422 × 10−2 1 log 2.22 × 10
HSV-1 5.01 × 10−3 8.97 × 10−1 2 log 0.55 × 102
Note: aVirus titer reduction: the extract is considered active if the virus titer was reduced by 2 log. bReduction factor (RF): virus titer in the absence of drug over
virus titer in the presence of drug. RF ≥ 103 strong antiviral activity, RF = 102 moderate antiviral activity and RF =101 slight antiviral activity
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in Vero cells whereas, 50 % CPE in Vero cells was observed
after 30 min and 1 h with concentration 27.62 mg/ml of
MBS extract (Table 2). The Lowest concentration of MBS
extract enough to inhibit HSV-1 CPE completely after
(zero, 1, and 2 h) of incubation with the virus before adding
to MRC-5 cells was 136.58 mg/ml. In comparison to the
direct effect of MBS extract on RSV, 25 % of HSV-1 CPE
was observed with only 68.29 mg/ml of the extract when
mixed together with the virus and applied directly to MRC-
5 while MBS extract at concentrations 17.07 and 8.53 mg/
ml were capable to inhibit 50 % CPE after 1 and 2 h of in-
cubation with the virus. The indirect effect of MBS extract,
which was estimated by incubating the extract with MRC-5
cells, was clearly different from the same effect on Vero
cells. Here, the extract needed only the concentration of
(17.07 mg/ml) to reduce the CPE to 50 % after 30 min and
1 h of incubation with the cells (Table 3).
MBS extract at concentration of 220.96 mg/ml caused
50 % cytotoxicity (CC50) on Vero cells (specific cells for
RSV) while only 136.58 mg/ml was enough to cause the
50 % death (CC50) in MRC-5 cell line (specific cells for
HSV-1). The significant direct antiviral activity of MBS
extract on RSV was observed when the extract incubated
with the virus for 1 h then applied to Vero cells (IC50 =
15.62 mg/ml) in comparison to zero hour and 2 h of in-
cubation which were found to be less active (P < 0.05).
These significant findings were supported by the results
of the SI, 14.18, for 1 h incubation time which was sig-
nificantly higher than that of zero hour, 8.35, and 2 h,
8.28 (P < 0.05). These results supported our findings
regarding the efficacy of 1 h incubation of virus with
MBS. Regarding the incubation of MBS extract with
Vero cells before the infection with RSV, the incubation
time of one hour was also the proper time to inhibit
50 % of RSV-induced CPE (IC50 = 17.23 mg/ml) which
gave SI of 12.82 when compared with 30 min of incuba-
tion. Therefore, 1 h time of incubation was found to be
the proper time for both direct virucidal effect of MBS
and indirect inhibition of virus replication by treating
Vero cells with MBS. This incubation time was used to
investigate the antiviral effect of the standard drug
(Ribavirin) and compare it with MBS extract activity
(Tables 4, 5 and 6). On the other hand, when incubating
HSV-1 with MBS extract, it needed 2 h to inhibit 50 %
of its CPE on MRC-5 cells (IC50 = 7.62 mg/ml) which
was higher than that of zero or 1 h incubation times
(P < 0.05). The SI, 18.23 for 2 h reflected the same result
when compared to the SI of zero hour and 1 h, 5.69 and
9.91, respectively (P < 0.05). Two hours incubation was
used to estimate the antiviral activity of the standard drug
(Acyclovir) in order to be compared with that of MBS ex-
tract. MBS extract needed 1 h incubation time to induce
its prophylactic effect against HSV-1 when incubated with
MRC-5. It needed 1 h to give IC50 of 12.72 mg/ml and
resulted in SI of 10.9. This effective time of incubation,
i.e., 1 h to provide the prophylactic effect of MBS extract
was used to evaluate the same activity for Acyclovir. These
results reflected the fact that the direct effect of MBS
extract needed more time (about 2 h) to create effective SI
against HSV-1 while it needed only 1 h to generate such
effective SI against RSV (Tables 7, 8 and 9).
Comparison between the virucidal and the prophylactic
properties of MBS extract to RSV, and between that of
MBS extract and Ribavirin
The proper incubation time of each protocol for MBS
extract is compared together to find the best antiviral
activity. MBS extract was effective as both prophylactic
Table 2 RSV-induced CPE (%) after incubating the MBS extract
with the virus and with Vero cell line
Protocols Time aConc.1 Conc.2 Conc.3 Conc.4 Conc.5
bDVI 0 h 0 % 0-25 % 25-50 % 50 % 75 %
1 h 0 % 0 % 0-25 % 50 % 50-75 %
2 h 0 % 0 % 0 % 50 % 75 %
cIVR 30 min 0 % 0 % 25-50 % 50 % 50-75 %
1 h 0 % 0 % 0-25 % 25-50 % 50-75 %
Note: aConc.: extract concentration (220.96, 110.48, 55.24, 27.62, and 13.81 mg/ml).
bDVI: the direct virus inactivation. cIVR: the inhibition in virus infection after
specific cell treatment
Table 3 HSV-1 induced CPE (%) after incubating the MBS
extract with the virus and with MRC-5 cell line
Protocols Time aConc.1 Conc.2 Conc.3 Conc.4 Conc.5
bDVI 0 h 0 % 0-25 % 25-50 % 50-75 % 100 %
1 h 0 % 0 % 0-25 % 25-50 % 50-75 %
2 h 0 % 0 % 0 % 0-25 % 50 %
cIVR 30 min 0 % 0 % 25-50 % 50 % ≥75 %
1 h 0 % 0 % 0-25 % 25-50 % 50-75 %
Note: aConc.: extract concentration (136.58, 68.29, 34.14, 17.07, and 8.53 mg/ml).
bDVI: the direct virus inactivation. cIVR: the inhibition in virus infection after
specific cell treatment
Table 4 The antiviral activity of MBS extract on RSV by the
direct virucidal effect and the prophylactic effect on Vero cell
line
Protocol Time aCC50 mg/ml bIC50 mg/ml cSI
dDVI 0 h 220.96 ± 60.56 26.98 ± 2.82 8.35 ± 0.79
1 h 220.96 ± 60.56 15.62 ± 0.61 14.18 ± 0.54
2 h 220.96 ± 60.56 26.72 ± 0.95 8.28 ± 0.29
Ribavirin 1 h 1.4 ± 0.088 0.06 ± 0.005 23.39 ± 2.44
eIVR 30 min 220.96 ± 60.56 18.92 ± 0.47 11.69 ± 0.28
1 h 220.96 ± 60.56 17.23 ± 0.3 12.82 ± 0.23
Ribavirin 1 h 2.28 ± 0.057 0.087 ± 0.005 21.95 ± 2.12
Note: acytotoxic concentration 50, b Inhibitory concentration 50, c selective
index dDVI: the direct virus inactivation. eIVR: the inhibition in virus infection
after specific cell treatment
Hafidh et al. BMC Complementary and Alternative Medicine  (2015) 15:179 Page 3 of 16
and virucidal agent; however, it was a bit better as a viru-
cidal agent on RSV with (IC50 = 15.62 mg/ml) than as
prophylactic agent. This was shown by SI values which
were 14.18 and 12.82 for virucidal and prophylactic ac-
tivities, respectively (Tables 10 and 11).
Comparing with the anti-RSV activity of Ribavirin,
there were significant differences in the prophylactic
and virucidal effects of MBS extract and Ribavirin
(P < 0.05) at the same time of incubation. The results
revealed that the SI of MBS extract as prophylactic
agent (SI = 12.82) was less than that of Ribavirin (SI =
21.95). Furthermore, the level of MBS extract as a viru-
cidal agent (SI = 14.18) was lower than that of Ribavirin
(SI = 23.39), (Table 11).
Comparison between the virucidal and the prophylactic
properties of MBS extract to HSV-1, and between that of
MBS extract and Acyclovir
By using the best incubation time that generated a sig-
nificant antiviral activity against HSV-1, the prophylactic
and virucidal effects of MBS extract were compared to-
gether. At time of incubation (2 h), MBS extract was
effective as virucidal and prophylactic agent but it was
most prominent as a virucidal agent against HSV-1 using
7.62 mg/ml MBS extract (Table 12). As shown in
(Table 12), there were significant differences (P < 0.05)
when comparing the SI values between different proto-
cols for MBS extract. In other words, the SI value, 18.23,
of the virucidal activity of MBS extract was significantly
higher than that of the prophylactic action.
In addition, MBS extract did not show any significant
difference when its prophylactic and virucidal activ-
ities were compared with that of Acyclovir (P > 0.05),
(Table 13).
The antiviral cytokines produced by the treated-viral
infected cells
The extracellular concentration of a group of cyto-
kines implicated in the antiviral response was moni-
tored in the supernatant of MRC-5 cells. The cells
were categorized into four groups. The first group
was MRC-5 cells cultured without exposure to either
extract or viral infection by HSV-1. The second group
was MRC-5 cells treated for one hour with IC50 of
IVR protocol of MBS extract alone. The third group
was MRC-5 cells infected with HSV-1. The fourth
group was MRC-5 cells pretreated with IC50 of IVR
protocol of MBS extract and cells were then infected with
HSV-1. Both the group of MBS treated cells and the group
of infected cells showed higher synthesis of all tested cyto-
kines, IFNβ, IL-1, IL-6, and TNFα than in control cells
(MBS treated cells: P = 0.005, 0.011, <0.001, <0.001; in-
fected cells: P = 0.009, 0.006, 0.041, 0.01, respectively).
Moreover, the level of IFNβ and IL-1 was not significantly
different between MBS treated cells and infected cells
(P = 0.75, 0.31, respectively) while the level of IL-6
and TNFα was higher in MBS treated cells than in
infected cells (P = 0.009, 0.025, respectively). These re-
sults indicated that MBS extract can induce the syn-
thesis of IL-6 and TNFα more strongly than the
synthesis of IFNβ and IL-1 (P < 0.05), (Table 14 and
Fig. 1). Above all, MBS extract induced synthesis of
all tested cytokines in MRC-5 cells infected with
HSV-1 far higher than all other groups (P < 0.001),
(Table 14 and Fig. 1). Moreover, MBS extract showed
a powerful prophylactic effect for MRC-5 cells against
viral infection by charging the MBS treated cells to
be ready and highly responsive against any viral
infection.
Table 5 The differences in 50 % inhibitory concentration (IC50) of MBS extract on RSV between the different times in the same
protocol (DVI and IVR)
Protocol Time vs Time IC50 vs IC50 P value
aDVI 0 h vs 1 h 26.98 ± 2.82 vs 15.62 ± 0.61 0.008 Significant
0 h vs 2 h 26.98 ± 2.82 vs 26.72 ± 0.95 0.46 Non-Significant
1 h vs 2 h 15.62 ± 0.61 vs 26.72 ± 0.95 0.0003 Significant
bIVR 30 min vs 1 h 18.92 ± 0.47 vs 17.23 ± 0.3 0.02 Significant
Note: aDVI: the direct virus inactivation. bIVR: the inhibition in virus infection after specific cell treatment
Table 6 The differences in selectivity index (SI) of MBS extract on RSV between the different times in the same protocol (DVI and IVR)
Protocol Time vs Time SI vs SI P value
aDVI 0 h vs 1 h 8.35 ± 0.79 vs 14.18 ± 0.54 0.001 Significant
0 h vs 2 h 8.35 ± 0.79 vs 8.28 ± 0.29 0.47 Non-Significant
1 h vs 2 h 14.18 ± 0.54 vs 8.28 ± 0.29 0.0003 Significant
bIVR 30 min vs 1 h 11.69 ± 0.28 vs 12.82 ± 0.23 0.018 Significant
Note: aDVI: the direct virus inactivation. bIVR: the inhibition in virus infection after specific cell treatment
Hafidh et al. BMC Complementary and Alternative Medicine  (2015) 15:179 Page 4 of 16
Discussion
Flavonoids, the most common polyphenols found in
plants, have been associated with biological effects such
as antibacterial, antiviral, anti-inflammatory, antiplatelet,
antioxidant, free radical scavenging, and vasodilatory
effects [9, 10]. MBS is known to have high antioxidant
activity which may be correlated with an effective anti-
viral activity.
To establish the efficacy of the antiviral activity of
MBS extract, virus yield reduction assay was performed
in which plant extract was added to host cells (Vero and
MRC-5) after infection with RSV and HSV-1, respectively.
The maximum non-cytotoxic concentration of MBS ex-
tract was able to reduce HSV-1 by 2 log (RF = 0.55 × 102)
and RSV only by 1 log (RF = 2.22 × 10) to give a moderate
and slight antiviral activity against HSV-1 and RSV,
respectively. These results reflected the efficacy of the
solvent, i.e., methanol, in extracting the antiviral compo-
nents from MBS. Moreover, the synergistic effect of these
extracted polyphenols may play a critical role in this activ-
ity. It was reported that methanol is the best solvent for
the consistent extraction of antimicrobial substances from
medicinal plants compared to other solvents such as
water, ethanol, or hexane [11]. The benefit of crude extract
over the fractionated extract is that the crude one is com-
posed of a large mixture of polyphenols that could inter-
play effectively giving rise to novel and antiviral activities.
It was stated that different polyphenolic components of a
plant extract may influence different steps of antimicrobial
activity in a synergistic manner [12].
MBS extract reduced virus titer in one to two logs.
Plant extracts are considered active if the virus titer was
reduced by one log and highly active by two logs after
treatment [7, 13]. Furthermore, any extract with RF
value of ≥ 10 should be considered highly valuable and
selected to determine the mode of its antiviral action
[14]. For these reasons, MBS extract was further ana-
lyzed to investigate its antiviral activities as well as their
modes of action to reduce RSV and HSV-1 titer.
The results showed that the antiviral activity of MBS
extract is dose-dependent. Concentrations of extract
close to the CC50 caused 100 % inhibition of CPE. How-
ever, much lower concentrations succeeded in reducing
virus CPE in large extent giving clue on the potent anti-
viral activity in MBS extract. MBS extract at concentra-
tion of 220.96 mg/ml caused death to 50 % of Vero cells
and at 136.58 mg/ml caused death in 50 % of MRC-5
cells. Therefore, CC50 values of MBS extract on both
Vero and MRC-5 cells are considered too high when
compared to the concentrations yielded 50 % antiviral
activity, IC50, which ranged from 7.62 to 15.62. These
figures of IC50 indicated high selectivity in the extract
activity. To elucidate this aspect, it was necessary to
calculate the selectivity index, i.e., the therapeutic index.
It is generally considered that biological efficacy is not
due to in vitro cytotoxicity when SI ≥ 10 [15, 16].
The results of MBS extract cytotoxicity on the virus
host cells (Vero and MRC-5 cells) were in correlation
with the effective concentration which was needed to in-
hibit virus-induced CPE. The study’s results found that
MBS extract was needed in lower concentrations to in-
hibit HSV-1 induced CPE than that needed to inhibit
RSV-induced CPE. This depended on the CC50 values
of MBS extract on MRC-5 and Vero cells. The results
disclosed the fact that MBS extract was more cytotoxic
to MRC-5 cells (CC50 = 136.58 mg/ml) than to Vero
cells (CC50 = 220.96 mg/ml). In other words, Vero cells
can tolerate higher MBS extract concentrations than can
MRC-5 cells. Fortunately, the high cytotoxicity of MBS
extract against MRC-5 was accompanied with high
antiviral activity against HSV-1 leading to attain low
working antiviral concentrations much lower than the
Table 7 The antiviral activity of MBS extract on HSV-1 by the
direct virucidal effect and the prophylactic effect on MRC-5 cell
line
Protocol Time aCC50 mg/ml b IC50 mg/ml cSI
dDVI 0 h 136.58 ± 55.08 24.17 ± 1.43 5.69 ± 0.35
1 h 136.58 ± 55.08 13.8 ± 0.44 9.91 ± 0.31
2 h 136.58 ± 55.08 7.62 ± 0.71 18.23 ± 1.69
Acyclovir 2 h 0.35 ± 0.005 0.014 ± 0.0005 22.56 ± 1.11
eIVR 30 min 136.58 ± 55.08 15.53 ± 0.74 8.83 ± 0.42
1 h 136.58 ± 55.08 12.72 ± 1.12 10.9 ± 0.96
Acyclovir 1 h 0.37 ± 0.005 0.02 ± 0.003 15.04 ± 1.9
Note: a cytotoxic concentration 50, b Inhibitory concentration 50, c selective
index dDVI: the direct virus inactivation. eIVR: the inhibition in virus infection
after specific cell treatment
Table 8 The differences in the 50 % inhibitory concentration (IC50) of MBS extract on HSV-1 between the different times in the
same protocol (DVI and IVR)
Protocol Time vs Time IC50 vs IC50 P value
aDVI 0 h vs 1 h 24.17 ± 1.43 vs 13.8 ± 0.44 0.001 Significant
0 h vs 2 h 24.17 ± 1.43 vs 7.62 ± 0.71 0.0002 Significant
1 h vs 2 h 13.8 ± 0.44 vs 7.62 ± 0.71 0.0009 Significant
bIVR 30 min vs 1 h 15.53 ± 0.74 vs 12.72 ± 1.12 0.05 Non-Significant
Note: aDVI: the direct virus inactivation. bIVR: the inhibition in virus infection after specific cell treatment
Hafidh et al. BMC Complementary and Alternative Medicine  (2015) 15:179 Page 5 of 16
cytotoxic concentrations for the host cells. The max-
imum non-cytotoxic concentrations (CC50) of MBS
extract for both Vero and MRC-5 cells showed sig-
nificant reduction of RSV- and HSV-1- induced CPE
by 100 %. This can be attributed to the cytotoxicity
of the extract used for the host cells; however, the
lower 2-fold concentration of the MBS extract showed the
same 100 % inhibition of viral CPE for treatments 1 h and
2 h. This indicated a specific antiviral activity rather than
viral reduction due to cytotoxicity of host cells.
The IVR treatments by MBS extract showed optimal
time of 1 h rather than 30 min for both Vero and MRC-5
cells while in DVI treatments, 1 h and 2 h were optimal
for RSV and HSV-1, respectively. Accordingly, 2 h were
enough for HSV-1 while just 1 h was enough for RSV.
This provided evidence that HSV-1 needs longer expo-
sures than RSV with antiviral agents to respond efficiently.
The SI of MBS extract after 1 h of incubation was
quite high (14.18), pointing out to a high selectivity in
the extract action. Accordingly, 1 h of RSV treatment
with MBS extract was the proper time to inhibit virus-
induced CPE by 50 % with much lower cytotoxicity on
the host cells (Vero cells) and significant selectivity on
the virus. In addition, the SI of MBS extract treatment
for Vero cells before being infected with RSV, namely,
IVR protocol, was (12.82), which indicated also a high
selectivity in the extract action over the cytotoxicity to
Vero cells. The activity of MBS extract on RSV in this
study may agree with a previous study which found that
the methanol crude extract of some plants is highly effect-
ive to inhibit RSV and can be considered the best choice
in searching for novel antiviral agents for RSV [17].
The selectivity, SI, of 2 h treatment of MBS extract for
HSV-1 was very high (18.23) while SI for 1 h treatment,
via IVR, of MBS extract to the host cells (MRC-5 cells)
before being infected with HSV-1 was just acceptable,
10.9. The antiviral activities of MBS extract in both DVI
and IVR for RSV in Vero cells and HSV-1 in MRC-5
cells gave many indications. First, MBS extract acted as
a potent antiviral agent and its action was not related to
the cytotoxicity of host cells. Second, MBS extract was
highly selective against RSV and HSV-1 or against the
virally infected cells. Third, MBS extract, acted as viru-
cidal agent more than prophylactic agent. These valuable
results of MBS extract anti-HSV1 activity may be sup-
ported by a recent study on plant methanol crude ex-
tract which found that such extract found to be effective
to inhibit HSV-1 infection in vitro [18]. The results of
MBS extract, IC50 and SI, with different modes of action
against RSV were significantly better in its virucidal ac-
tion (IC50 = 15.62 and SI = 14.18) than its prophylactic
action (IC50 = 17.23 and SI = 12.82). Similarly, MBS ex-
tract was a virucidal agent (IC50 = 7.62 and SI = 18.23)
rather than a prophylactic agent (IC50 = 12.72 and SI =
10.9) against HSV-1. These findings may point out to
the importance of MBS extract as an agent with the abil-
ity to interact with viral envelope more sufficiently than
its ability to interact with host cell surface. One of the
clear reasons that may explain the effective antiviral ac-
tivity of MBS extract in the current study is the presence
of high level of antioxidant compounds in the germi-
nated mung bean sprout. Germination of the mung bean
causes a rise in total content of the antioxidant com-
ponents like phenolic compounds, α-tocopherol and
vitamin C [19, 20]. It is well known that α-tocopherol, a
member of vitamin E family, has a potent antioxidant
activity [21, 22]. Moreover, many studies proved the effi-
cacy of α-tocopherol as antithrombotic, anticoagulant,
neuroprotective, antiproliferative, immunomodulatory,
cell membrane-stabilizing and antiviral [23–25]. On the
other hand, ascorbate (Vitamin C) has been shown to
have specific antiviral effect in which it inactivates RNA
or DNA of viruses [26–28]. Moreover, ascorbate was
found to be able to act synergistically with other phen-
olic compounds to enhance their antiviral activity [29].
All these facts may explain the effective antiviral activity
of MBS extract. The ability of each antioxidant compound
to work alone or with other compounds to enhance its
Table 9 The differences in selectivity index (SI) of MBS extract on HSV-1 between the different times in the same protocol (DVI and IVR)
Protocol Time vs Time SI vs SI P value
aDVI 0 h vs 1 h 5.69 ± 0.35 vs 9.91 ± 0.31 0.0004 Significant
0 h vs 2 h 5.69 ± 0.35 vs 18.23 ± 1.69 0.0009 Significant
1 h vs 2 h 9.91 ± 0.31 vs 18.23 ± 1.69 0.004 Significant
bIVR 30 min vs 1 h 8.83 ± 0.42 vs 10.9 ± 0.96 0.06 Non-Significant
Note: aDVI: the direct virus inactivation. bIVR: the inhibition in virus infection after specific cell treatment
Table 10 Comparisons of the 50 % inhibitory concentration (IC50) of MBS extract on RSV at the best time for each protocol
Protocol vs Protocol Time vs Time IC50 vs IC50 mg/ml P value
aIVR vs bDVI 1 h vs 1 h 17.23 ± 0.3 vs 15.62 ± 0.61 0.03 Significant
Note: aIVR: the inhibition in virus infection after specific cell treatment. bDVI: the direct virus inactivation
Hafidh et al. BMC Complementary and Alternative Medicine  (2015) 15:179 Page 6 of 16
effect in the antiviral activity was well proven by some
studies [23, 24, 26]. These studies suggested that the po-
tent antioxidant activity that leads to antimicrobial activity
is a result of a combination of different compounds having
synergistic effect [30].
The acute respiratory illness due to RSV is one of the
most common causes of hospitalization in very young
children worldwide and treatment remains supportive.
Ribavirin is approved for the treatment of severe RSV
disease; however, its effectiveness in improving outcomes
is questionable [31–33]. Additionally, the clinical treat-
ment with Ribavirin requires high doses with significant
side effects including thrombocytosis and severe anemia
[34, 35]. All these factors together raise the critical need
for a new, safe, and effective antiviral agent to win the
battle against RSV.
Despite the fact that MBS extract worked as a viru-
cidal agent (SI = 14.18) more powerfully than as a
prophylactic agent (SI = 12.82) against RSV, this activity
was not better than the activity of Ribavirin. Both DVI
and IVR antiviral activities of MBS extract showed
significant differences from that of Ribavirin. Thus, MBS
extract had effective virucidal activity against RSV (SI =
14.18) but it is still not much like the virucidal activity
of Ribavirin (SI = 23.39). However, MBS extract might
harbor some advantages over ribavarin such as safety,
low cost, and its natural origin which together allow
using MBS extract, and/or the underlying antiviral
component, in higher doses and longer periods than
ribavarin; this ultimately leads to equal or superior the-
rapeutic values of MBS extract to that of ribavarin. For
these reasons, the current trend of searching antimi-
crobial has moved to the natural products for the direct
use of natural extracts or the use of the responsible anti-
microbial component.
HSV-1 can establish latent infection in the nervous
system and usually leads to life-threatening diseases in
immunocompromised individuals upon reactivation [36].
Treatment with conventional nucleoside analogues such
as Acyclovir is effective in most cases, but drug-resistance
may arise due to prolonged treatment in immuno-
compromised individuals [37]. The recovery of the same
Acyclovir-resistant virus during recurrent infections sug-
gests that Acyclovir-resistant HSV-1 establishes latency
and reactivates intermittently in highly risk individuals
[38]. Moreover, a well-known side effect of prolonged
Acyclovir treatment is kidney nephrotoxicity [39]. Accord-
ingly, it is conceived so far that the plants’ derived anti-
HSV1 drugs might be the only way that can solve these
problems.
MBS extract showed higher virucidal than prophylac-
tic activities against HSV-1. However, both activities
were well evident. The virucidal activity against HSV-1
was high (SI = 18.23) and the prophylactic activity was
fair enough to be considered effective (SI = 10.9) against
HSV-1 infection. But the most interesting, there was no
significant difference found between the prophylactic
and the virucidal actions of MBS extract and that of the
HSV-1 standard drug, Acyclovir. Accordingly, MBS
extract could be used in the treatment and/or in the
prophylaxis of HSV-1 against HSV-1 infection at com-
parable levels to that of Acyclovir.
MBS extract showed capability for killing HSV-1 and
RSV viruses which is a sign for a prominent virucidal ac-
tivity. In addition, it exerted antiviral prophylactic activ-
ity in both Vero cells and MRC-5 host cells against both
RSV and HSV-1 viruses, respectively. Therefore, there
was a need to elucidate part of the underlying mecha-
nism(s) exerted by this extract on protecting virus-specific
host cells against the infection and cytopathic effects of
the tested viruses. For this goal, the induction for the
synthesis of four cytokines known as actively engaged in
the antiviral activity of mammalian cells against RNA and
DNA viruses, namely IFNβ, IL-1, IL-6, and TNFα, was
studied [40–47].
Starting with the most prominent antiviral cytokine,
IFNβ, this cytokine was remarkably induced by MBS
extract in extract-pretreated HSV-1-infected MRC-5
cells. In addition, this extract induced IFNβ expression
in non-infected cells treated with this extract. These
Table 11 Comparisons of the selectivity index (SI) of antiviral activity on RSV between prophylactic (IVR) and virucidal (DVI) at best
time for MBS extract and between that of MBS extract and the standard drug (Ribavirin)
Extract Protocol vs Protocol Time vs Time SI vs SI P value
MBS aIVR vs bDVI 1 h vs 1 h 12.82 ± 0.23 vs 14.18 ± 0.54 0.04 Significant
MBS vs Ribavirin aIVR vs aIVR 1 h vs 1 h 12.82 ± 0.23 vs 21.95 ± 2.12 0.006 Significant
MBS vs Ribavirin bDVI vs bDVI 1 h vs 1 h 14.18 ± 0.54 vs 23.39 ± 2.44 0.01 Significant
Note: aIVR: the inhibition in virus infection after specific cell treatment. bDVI: the direct virus inactivation
Table 12 Comparisons of the 50 % inhibitory concentration (IC50) of MBS extract on HSV-1 at the best time for each protocol
Protocol vs Protocol Time vs Time IC50 vs IC50 P value
aIVR vs bDVI 1 h vs 2 h 12.72 ± 1.12 vs 7.62 ± 0.71 0.009 Significant
Note: aIVR: the inhibition in virus infection after specific cell treatment. bDVI: the direct virus inactivation
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findings provided evidence on the ability of MBS extract
to charge human cells ready for any concurrent and sub-
sequent viral infections. However, the interesting feature
which was found here that MBS extract induced IFNβ in
non-infected cells much lower than in infected cells.
This feature adds privilege on using MBS extract or the
antiviral components that will be isolated from it be-
cause these agents selectively induce IFNβ most highly
in infected cells only. Therefore, using MBS extract might
override the side effects of using interferons therapy which
usually causes febrile reaction, headache, and unwanted
systematic immune reactions [48, 49].
For TNFα, this cytokine was recently found to be import-
ant antiviral as well as anticancer cytokine [41, 43, 50–52].
MBS extract showed good inducing capacity for TNFα
expression by MRC-5 cells. The highest level of TNFα in-
duction by MBS extract was observed in treated-infected
cells followed by treated cells, infected cells, and finally by
control cells (non-treated non-infected cells). These find-
ings granted clues on the ability of MBS extract to select-
ively induce higher levels of TNFα by human cells when
these cells are being infected by viruses. Therefore, MRC-
5 cells needed two signals for the expression of the
maximum levels of TNFα; these signals came from the
extracts’ pretreatment and HSV-1 infection. Like the case
of IFNβ, the relatively selective induction of TNFα expres-
sion in virally infected human cells pretreated with MBS
extract can also override the systemic side effects for using
synthetic TNFα products [53]. Wei et al. found that TNFα
levels, locally and systematically, increase significantly in
mice with HSV-1 infection; moreover, after treatment with
Acyclovir for HSV-1 infection, the level of TNFα was
largely decreased [54]. This report revealed the pivotal role
of TNFα in counteracting DNA viruses such as HSV-1. As
a proof for the strong link between TNFα induction and
viral infection, mainly by HSV-1, a previous study [43]
found that TNFα and IL-1 cytokines were produced
largely by microglial cells during non-productive infection
while other cytokines, including interferons, were not in-
duced by such weak infective cycle. It was revealed that
TNF induce multiple antiviral mechanisms, and to syner-
gize with interferon (IFN)-gamma in promoting antiviral
activities; and the antiviral activity of TNF is mediated via
both TNF receptors, TNFR1 (p55) and TNFR2 (p75), in
vivo [55]. Recently, it was found that the combination of
TNFα and IFNβ induces a novel synergistic antiviral state
that is highly distinct from that induced by either cytokine
alone [56]. Hence, MBS extract is believed to exert a syn-
ergistic antiviral effect by inducing both TNFα and IFNβ
cytokines.
Several reports proved the antiviral role of IL-1 and
IL-6 in human and murine cells [43, 46, 47, 57–60]. The
expression of IL-1 was highest in treated-infected cells,
followed equally by treated cells alone and infected cells
alone, and finally the control cells. For IL-6, the highest
expression was in treated-infected cells, followed by
treated cells, infected cells, and control cells. Like the
case of TNFα and IFNβ, MBS extract induced the high-
est level of expression of IL-1 and IL-6 in HSV-1 in-
fected cells already treated with the extract. Thus MBS
extract showed selectivity in inducing all tested cyto-
kines. This phenomenon points out to the possibility
that TNFα, IFNβ, IL-1, and IL-6 are induced by MBS ex-
tract via the same mechanism(s). One of the proposed
mechanisms to induce all these cytokines to create anti-
viral resistance is the induction of nuclear factor-kappa
B (NF-kappa-B), transcriptional factor. Recent reports
stated and proved the antiviral role of NF-kappa-B
[61, 62]. Moreover, antiviral resistance against HSV-1 via
TNFα was found to be attributed to NF-kappa-B [42].
Table 13 Comparisons of the selectivity index (SI) of antiviral activity on HSV-1 between prophylactic (IVR) and virucidal (DVI) at best
time for MBS extract and between that of MBS extract and the standard drug (Acyclovir)
Extract Protocol vs Protocol Time vs Time SI vs SI P value
MBS aIVR vs bDVI 1 h vs 2 h 10.9 ± 0.96 vs 18.23 ± 1.69 0.009 Significant
MBS vs Acyclovir aIVR vs aIVR 1 h vs 1 h 10.9 ± 0.96 vs 15.04 ± 1.9 0.06 Non-significant
MBS vs Acyclovir bDVI vs bDVI 2 h vs 2 h 18.23 ± 1.69 vs 22.56 ± 1.11 0.05 Non- Significant
Note: aIVR: the inhibition in virus infection after specific cell treatment. bDVI: the direct virus inactivation
Table 14 The measured concentrations of antiviral cytokines in control, MBS extract treated, HSV-1 infected, and MBS extract treated &
HSV-1 infected MRC-5 cells
Cytokine Control cells
Mean ± 2SE (pg/ml)
Treated cells
Mean ± 2SE (pg/ml)
Infected cells
Mean ± 2SE (pg/ml)
Treated-infected cells
Mean ± 2SE (pg/ml)
IFNβ 53.7 ± 5.72 91.78 ± 7.98 88.49 ± 7.49 181.42 ± 15.6
IL-1 36.84 ± 6.22 76.16 ± 9.24 90.58 ± 9.32 145.72 ± 13.51
IL-6 58.11 ± 3.85 115.24 ± 10.1 75.92 ± 11.54 190.31 ± 10.6
TNFα 40.3 ± 4.81 105.97 ± 8.42 79.43 ± 10.04 174.67 ± 14.77
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Conclusion
The primary antiviral assay revealed noticeable antiviral
activities against RSV and HSV-1 by MBS extract. The
SI reflected high selectivity and low cytotoxicity of MBS
extract over RSV, Vero cells, HSV-1, and MRC-5, re-
spectively. MBS extract was more effective as a virucidal
agent than a prophylactic agent on RSV and HSV-1.
Hence, MBS extract can be used in the treatment and in
the prophylaxis against both HSV-1 and RSV infection
with comparable levels to that of standard drugs but
with much more safety. MBS extract revealed ability to
create a highly inducible status in virally infected cells
for the expression of high levels of IFNβ, TNFα, IL-1,
and IL-6 cytokines which may explain in part its prophy-
lactic activity. These cytokines proved to play essential
and synergistic role in the antiviral resistance of human
cells. Collectively, the importance of these results comes
from their novelty. The effective anti-RSV and anti-
HSV1 activities of MBS extract were significant. The
findings of this study may open the gate wide to develop
new antiviral agents from inexpensive and safe sources
like mung bean sprout.
Methods
Preparation of the MBS extract
Fresh mung bean sprouts (MBS), devoid of any preserva-
tive antimicrobials, was purchased from local markets
and were identified by the leader of the research team,
namely Dr. Fatimah Abu Bakar. A voucher specimen of
MBS has not been deposited in a publicly available herb-
arium as MBS used is that of the daily used produce.
The mung bean sprouts were left to dry in dark area for
three days at room temperature 23-25 °C. After the
dryness of sprouts, they were ground to powder. The
ground powder was extracted 1:10 wt/v with 2.4 M HCl
acidified methanol (Merck, Darmstadt, Germany) to
extract all components of phenolic compounds, free and
conjugated, [63]; the ground powder was then soaked in
dark area for three days at room temperature. The
supernatant was collected after filtration and the fresh
solvent was added to the plant material. The extraction
procedure was repeated twice and the collected extract
was evaporated to dryness under vacuum at 40 °C by
using rotary evaporator. To remove the effect of the acid-
ity from the crude extract, the crude extract was neutral-
ized. The pH of MBS extract was adjusted to be neutral
ranging from 6.8 to 7.0. The dried extract was stored
at −18 °C in a desiccant form until further use.
Preparation of the stock extract
The stock extract for MBS was prepared by redissolving
in dimethyl sulfoxide (DMSO) 0.1 %, (BIO BASIC INC.,
NY, USA). This concentration was shown to be non toxic
to cell culture [64]. The dissolved suspension was cen-
trifuged at 134 g for 10 min and filtrated by 0.22 μm
Millipore filters (Nalgene, UK). The stock was stored
at −20 °C until it further use. The concentration of the
stock extract was determined as required.
Specific cells propagation and cryopreservation
African green monkey kidney cells (Vero; ATCC CCL-81)
were used to culture human respiratory syncytial virus
(RSV strain A-2: ATCC VR-1540) and human herpes sim-
plex virus type 1 (HSV-1 strain HF: ATCC VR-260) while
human embryonic lung fibroblast cells (MRC-5; ATCC
CCL-171) were used to culture human herpes simplex
virus type 1 (HSV-1 strain HF: ATCC VR-260) only. Cells
were propagated as monolayer at 37 °C under a humidi-
fied 5 % CO2 atmosphere in Roswell Park Memorial
Institute-1640 (RPMI-1640) culture medium w/L-glu-
tamine (biowest, Florida, USA) supplemented with Fetal
Bovine Serum (FBS) 10 %, (Sigma, Germany), 50 U/ml
penicillin-streptomycin (biowest, Florida, USA), and
2.5 μg/ml amphotericin B (biowest, Florida, USA). Part of
the cells were cryopreserved for future work in liquid ni-
trogen (−196 °C) after suspending them in RPMI-1640
cryospreserved medium supplemented with FBS 10 %,
DMSO 20 %, 50 U/ml of penicillin-streptomycin, and
2.5 μg/ml amphotericin B.
Virus propagation (RSV and HSV-1)
RSV and HSV-1 were propagated on 70-80 % and 90 %
confluent Vero cell monolayer, respectively, in RPMI-
1640 maintenance medium with 2 % FBS and antibiotics
as described above. Viruses were stored at −80 °C until
they were used again.
Fig. 1 A histogram shows the mean ± 2SE of the extracellular
concentration of IFNβ, IL-1, IL-6, and TNFα cytokines in the supernatant
of cultured control, MBS extract treated, HSV-1 infected, and MBS
extract treated & HSV-1 infected MRC-5 cells
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RSV titration by endpoint titration technique
Vero cells of 1 × 105 cell/well were grown in RPMI-1640
culture medium in 96-well flat-bottom tissue culture
plates (Orange Scientific, Europe). After 24 h of incuba-
tion, the medium was removed and the monolayer cells
were incubated for one and half hour at 37 °C with serial
10-fold diluted virus suspensions in phosphate buffer sa-
line (PBS), (CALBIOCHEM, Darmstadt, Germany). After
adsorption, the inoculum was removed and 200 μl/well
RPMI-1640 maintenance medium with 2 % FBS were
added. Negative Control wells represented Vero cells
without virus. All plates were incubated at 37 °C in a hu-
midified 5 % CO2 atmosphere and were observed daily for
cytopathic effect (CPE). Estimation of the endpoints was
made after 48 h. Titers were calculated as 50 % tissue cul-
ture infectious doses (TCID50)/ml, using the Reed and
Muench method [65] to estimate endpoints. The titration
was repeated for three times with four replicates for each
virus dilution at each time.
HSV-1 titration by plaque assay
HSV-1 was titrated using plaque assay. For this purpose
Vero cells of 1 × 105 cell/well were grown in RPMI-1640
culture medium using 6-well tissue culture plates (Or-
ange Scientific, Europe). After 24 h, the medium was re-
moved and the monolayer cells were incubated with
serial 10-fold diluted virus suspensions in PBS for 1 h at
37 °C. After removing the inoculum, the infected and
non infected cells were overlaid with RPMI-1640 culture
medium containing 0.5 % agarose type VII (Sigma,
Steinheim, Germany). Negative control wells represented
Vero cells without virus. After 48 h, the infected cells were
fixed by 1 % formaldehyede (Sigma, Steinheim, Germany)
for three days at room temperature. Afterwards, the agar-
ose layer was removed and the infected cells were stained
by 0.05 % neutral red (Sigma, Steinheim, Germany) for
2 h at room temperature. Plaques were counted and virus
titers expressed as plaque forming units (PFU)/ml
[36, 66]. The titration was repeated for three times with
two replicates for each virus dilution at each time.
Cytotoxicity assay
The cytotoxic activities of MBS extract and standard
antiviral drugs on virus specific cells were evaluated
using MTT assay. In this colorimetric assay, yellow
MTT 3-[4,5-dimethylthiazol-2-yl]-2,-diphenyltetrazolium
bromide, (CALBIOCHEM, Darmstadt, Germany) is re-
duced to purple formazan by live cells’ mitochondrial
enzymes [67, 68] and the color change can be quantified
by measuring the absorbance at certain wavelength.
After incubating the virus-specific cells with each extract
or the standard drugs, 50 μl MTT (5 mg/ml) and 200 μl
of RPMI-1640 culture medium were added to each well.
The plates were incubated in a humidified 5 % CO2
atmosphere for 4 h at 37 °C. Later, 200 μl/well DMSO
was added to solublize the formazan crystal. The plates
were shaked for 10 min and the absorbance was mea-
sured at 540 nm (reference 690 nm) using a 96-well
plate ELISA reader (Sunrise Basic Tecan, Grödig,
Austria). Each experiment was repeated for three times
with four wells per dilution in each run. The 50 % cyto-
toxic concentration (CC50) was defined as the highest
concentration that caused 50 % death or was cytotoxic
to 50 % of virus-specific cells. Cytotoxicity was calculated
using the following formula:
Cytotoxic % ¼ 100 – ODt = ODcð Þ  100½ 
Where (ODt) indicates the optical density of the
treated cells and (ODc) indicates the optical density of
the negative control or the untreated cells [15].
The cytotoxic effects of MBS extract on vero and MRC-5 cells
Vero cells were cultivated as 1 × 105 cell/well in 96-well
flat bottom tissue culture plates. MRC-5 cells were culti-
vated as 3 × 104 cell/well in 96-well flat bottom tissue
culture plates. After 24 h of incubation at 37 °C in a
humidified 5 % CO2 atmosphere, the monolayer cells
were exposed to 2-fold serial dilutions of MBS extract
in RPMI-1640 maintenance medium. Stock extract
(600 mg/ml) was used in this assay. MBS serial dilutions
ranged from 300 to 9.37 mg/ml. Each well contained
100 μl of extract dilution and 100 μl of RPMI-1640 main-
tenance medium. The negative control wells contained
100 μl of solvent (0.1 % DMSO) and 100 μl of RPMI-1640
maintenance medium. All the plates were incubated
for another 24 h in the same conditions. Afterwards,
the wells’ contents were removed and replaced with
200 μl/well maintenance medium; then, plates were
incubated for 48 h at the same conditions. The effects
of the extract were monitored daily though micro-
scopic examination.
The cytotoxic effect of the standard drugs ribavirin and
acyclovir
The cytotoxic activity of the RSV standard drug Ribavirin
(Sigma, Steinheim, Germany) and the cytotoxic effect of
the HSV-1 standard drug Acyclovir (Sigma, Steinheim,
Germany) were determined in order to calculate the CC50
for these two standard drugs. Vero (1 × 105 cell/well) and
MRC-5 (3 × 104 cell/well) cells were cultured in 96-well flat
bottom tissue culture plates with RPMI-1640 culture
medium. After 24 h of incubation at 37 °C in humidified
5 % CO2, all the wells’ contents were removed and the cells
were incubated with 2-fold serial dilutions of Ribavirin and
Acyclovir prepared in RPMI-1640 maintenance medium
with final volume of 200 μl/well. Negative control wells
contained cells with maintenance medium (200 μl/well).
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All the plates were incubated for 24 h at the same con-
ditions. The Ribavirin and Acyclovir stock solutions
(1 mg/ml and 0.06 mg/ml, respectively) were prepared
in PBS solution at serial dilutions ranged from 0.5 to
0.007 and 0.03 to 0.0005 mg/ml, respecitvely. After
24 h, the wells’ contents were removed and replaced
with 200 μl/well maintenance medium. The plates were
incubated for another 48 h at the same conditions. The
cells condition was microscopically checked daily.
Virus yield reduction assay
The antiviral activities of MBS extract on RSV and HSV-1
yields were evaluated to calculate the virus titer reduction
factor (RF). RF represents the virus titer in the ab-
sence of a drug over the virus titer in the presence of a
drug. RF ≥ 103 shows a strong antiviral activity, RF = 102
shows a moderate antiviral activity and RF =101 shows
slight antiviral activity [13, 14].
RSV and HSV-1 yield reduction assays
This experiment was performed according to the
method described by [69] with some modifications for
RSV and by Suzutani and Behbahani and with some
modifications [70, 71] for HSV-1. For RSV, Vero cells
were cultivated as 1 × 105 cell/well in 96-well flat bottom
culture plates in RPMI-1640 culture medium and for
HSV-1, MRC-5 cells were cultivated as (3 × 104 cell/well)
in 96-well flat bottom culture plates in RPMI-1640 culture
medium. After 24 h of incubation at 37 °C in a humidified
5 % CO2 atmosphere, the medium was removed and the
cell monolayer was exposed to 100 μl/well of RSV virus
suspension in PBS of 3.16 × 103 TCID50/ml for 1.30 h and
in the case of HSV-1, the virus suspension was in PBS as
5.01 × 103 PFU/ml for 1 h.
The virus suspension was removed and replaced with
200 μl/well of the extract non-cytotoxic 2-fold serial
dilutions (100 μl/well) and RPMI-1640 maintenance
medium (100 μl/well). Only 200 μl/well of RPMI-1640
maintenance medium was added to the positive and
negative control wells. The positive control wells con-
tained cells with virus without treatment. The negative
control wells contained cells with maintenance medium
only without virus and without treatment. For RSV, the
stock extract of MBS used was 441.92 mg/ml at serial
dilutions ranging from 220.96 to 13.81 mg/ml while, for
HSV-1, the stock solution was 273.16 mg/ml at serial
dilutions ranging from 136.58 to 8.53 mg/ml. All the
plates were incubated in a humidified 5 % CO2 atmos-
phere for 48 h (RSV) and 24 h (HSV-1) at 37 °C. Later,
three steps of freezing at −80 °C and thawing at 37 °C
were performed (10 min for each step). The cell mono-
layer was disrupted and transferred to 1.5 microtubes
(Eppendrof, Hamberg, Germany); then it was centrifuged
at 2150 g for 10 min. Two hundred microliters of RSV-
infected Vero cells and 500 ul of HSV-1-infected MRC-5
cells treated with each MBS extract dilution were trans-
ferred to a second Vero cell monolayer already cultured
in 24-well culture plates for RSV and 6-well culture
plates for HSV-1 (Orange Scientific, Europe). Serial 2-
fold dilutions of infected Vero cells from the primary
plate were prepared in the secondary plates. Each well
contained the infected Vero cells from the primary
plate, which was exposed to certain extract dilution,
plus RPMI-1640 maintenance medium with the final
volume of 200 μl/well for RSV and 500 ul/well for
HSV-1 except for the first well which contained the
infected Vero cells from the primary plate without diluting
RPMI-1640 medium. The virus suspensions from the
positive control wells of primary plates were transferred to
the positive control wells in the secondary plates. All of
the plates were incubated for 1.30 h and 1 h for RSV and
HSV-1 adsorption, respectively. Then, for RSV, all of the
wells’ contents were removed and replaced with 500 μl
RPMI-1640 maintenance medium and incubated in a
humidified 5 % CO2 atmosphere for 48 h at 37 °C. The
negative control wells contained cells without virus or the
initial extract dilution. The primary and secondary plates’
preparations were repeated three times with four repli-
cates of the extract dilution. After 48 h the virus titer was
estimated by endpoint titration method as TCID50/ml see
section. For HSV-1, all the wells’ contents were removed
and the cells were overlaid with RPMI-1640 culture
medium containing 0.5 % agarose type VII. The next steps
were carried out as mentioned earlier in virus titration
using plaque assay. The primary and secondary plates
were repeated three times with four and two replicates to
each extract dilution for the primary and secondary plates,
respectively, in each run.
Virucidal activity assay
The virucidal activity assay determines the ability of
MBS extract to directly inactivate the extracellular RSV
and HSV-1. The viruses were incubated with the non
toxic concentrations of extract for different time inter-
vals. Then, the treated virus suspensions were trans-
ferred to a ready cell monolayer of virus specific cell line
and incubated for 72 h. In other words, cultures were
incubated until the wells containing infected cells with
untreated virus (positive control) showed complete
(100 %) cytopathic effect. In order to compare the anti-
viral activities of MBS extract with the antiviral activity
of the standard drug, the same steps were repeated using
the non-cytotoxic concentration of standard drug. The
standard drugs were incubated with the viruses for a
duration of time equal to that needed by the extracts to
cause significant virucidal activity. The cytopathic reduc-
tion assay was estimated by recording the level of the
virus-induced CPE after the incubation time and was
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recorded as CPE percentage in comparison with the
positive and negative controls, as follows: (0 % CPE),
(0-25 % CPE), (25-50 % CPE), (50-75 % CPE) and
(75-100 % CPE), [17, 72]. The concentration that reduced
50 % of CPE with respect to control virus was estimated
from the plots of the absorbance data obtained from MTT
assay. Moreover, in order to confirm the MTT assay
results, the monolayer was observed microscopically to
estimate virus-induced CPE% as mentioned above [73].
The concentration that reduced 50 % of CPE was also
defined as 50 % inhibitory concentration (IC50). IC50 was
determined as the lowest concentration of extract that
caused 50 % inhibition of the virus-induced CPE. It was
calculated using the following formula:
Inhibition % ¼ ODt – ODcvð Þ = ODcd – ODcvð Þ  100½ 
Where ODt is the test absorbance and ODcv and
ODcd are the absorbance of control virus and control
cell, respectively [74].
The selective index (SI), which is an important param-
eter to evaluate the antiviral activity, was calculated from
the ratio CC50/IC50 [75]. The assay was repeated three
times with four replicates for each test in each run.
Virucidal activity against RSV and HSV-1
The effects of non cytotoxic concentrations of MBS
extract on the extracellular RSV and HSV-1 were investi-
gated by incubating 3.16 × 103 TCID50/ml of RSV and
5.01 × 103 PFU/ml of HSV-1 suspensions in PBS with
2-fold serial dilutions of MBS extract. The MBS stock
extract was 441.92 mg/ml for RSV and 273.16 mg/ml
for HSV-1 at serial dilutions ranging from 220.96 to
13.81 mg/ml and 136.58 to 8.53 mg/ml, respectively.
Using 1.5 ml microtubes, 150 μl of virus suspension
were incubated with 150 μl of MBS extract serial di-
lution in RPMI-1640 maintenance medium. The tubes
were incubated in humidified 5 % CO2 at 37 °C for
zero, 1, and 2 h. Ninety six-well flat bottom tissue culture
plates with Vero cell monolayer (1 × 105 cell/well), for
RSV, and with MRC-5 cell monolayer (3 × 104 cell/well),
for HSV-1, were prepared in advance. The virus suspen-
sion with the extract serial dilutions of zero hour time of
incubation was directly transferred to the ready tissue
culture plates and incubated for 1.30 h to enable virus
adsorption. The same procedure was carried out for other
microtubes after 1 and 2 h time of incubation. After virus
adsorption, the wells’ contents were removed and replaced
with 200 μl/well maintenance medium and incubated for
72 h at the same conditions. Then, two hundred microli-
ters of maintenance medium were added to the negative
control wells (cells without virus or treatment) and to the
positive control wells (cells with virus and without treat-
ment), [76, 77].
The same procedure was repeated on Vero and MRC-
5 cell monolayers using the RSV standard drug ‘Ribavi-
rin’ and the HSV-1 standard drug ‘Acyclovir’ except for
the following differences: the non cytotoxic 2-fold serial
dilutions of Ribavarin and Acyclovir ranged from 2.28 to
0.018 mg/ml and 0.3516 to 0.0027 mg/ml prepared from
stock solutions (4.56 mg/ml) and (0.7 mg/ml) in PBS,
respectively. RSV was incubated with Ribavirin only
for 1 h before the addition to Vero cell monolayer in
96-well flat bottom tissue culture plates while HSV-1
was incubated only for 2 h with Acyclovir before the
addition to the ready MRC-5 cell monolayer in 96-well flat
bottom tissue culture plates.
Prophylactic activity assay
In order to evaluate the prophylactic activity of MBS
extract on virus specific cells, non cytotoxic extract serial
dilutions were incubated with the cells before the virus
addition. In order to compare the prophylactic activities of
MBS extract with the standard drug of each virus, the
standard drugs were incubated with the cells only for dur-
ation of time needed by the extract to show significant
prophylactic activity. The CPE% together with the concen-
tration that inhibited 50 % of virus-induced CPE or the
50 % inhibitory concentration (IC50) and the (SI) were
calculated as mentioned earlier. The assay was repeated
three times with four replicates for each well.
The prophylactic effects of the MBS extract on
Pre-RSV-infection vero cell line and Pre-HSV-1 infection
MRC-5 cell line
A monolayer of Vero cells (1 × 105 cell/well) and MRC-5
cells (3 × 104 cell/well) in 96-well flat bottom tissue
culture plates were treated with 2-fold serial dilutions
of MBS extract. The MBS stock extract was, for RSV,
441.92 mg/ml at serial dilutions from 220.96 to
13.81 mg/ml and, for HSV-1, 273.16 mg/ml at serial
dilutions from 136.58 to 8.53 mg/ml. The plates were
divided into two groups. The first group was incubated
with the extract for 30 min and the second group was
incubated with the extract for 1 h in humidified 5 % CO2
incubator at 37 °C. All of the plates contained extract dilu-
tions as well as RPMI-1640 maintenance medium with
the final volume of 200 μl/well. The wells’ contents were
removed after the incubation time for each group and the
RSV suspension of 3.16 × 103 TCID50/ml and HSV-1 sus-
pension 5.01 × 103 PFU/ml in PBS were added to all the
wells except for the negative control wells. The plates were
incubated for 1.30 h at the same conditions. After the
virus adsorption, the virus suspension was removed and
replaced with 200 μl/well of maintenance medium. The
positive control wells contained infected cells without
treatment. Two hundred microliters of maintenance
medium were added to the negative control wells (cells
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without virus or treatment). All of the plates were incu-
bated for 72 h at the same conditions [78, 79].
The prophylactic activity of the standard RSV drug
‘Ribavirin’ on Vero cell monolayer and the prophylactic
activity of HSV-1 standard drug ‘Acyclovir’ on MRC-5
cell monolayer were evaluated using the same procedure
described above except for the following differences: the
non cytotoxic 2-fold serial dilutions of Ribavarin ranged
from 2.28 to 0.018 mg/ml prepared from stock solution
of 4.56 mg/ml in PBS while the non cytotoxic 2-fold
serial dilutions ranged from 0.3516 to 0.0027 mg/ml pre-
pared from stock solution of 0.7 mg/ml in PBS. The cells
were incubated with Ribavirin for 1 h before the addition
of RSV to the ready Vero cell monolayer in 96-well flat
bottom tissue culture plates while the cells were
incubated with Acyclovir for 1 h before the addition of
HSV-1 to the ready MRC-5 cell monolayer in 96-well
flat bottom tissue culture plates.
Cytokine production by human embryonic fibroblast cell
lines (MRC-5) in response to HSV-1 infection and extract’s
treatment
The preparation of MRC-5 cells supernatants
The level of antiviral cytokines, IFNβ, TNFα, IL-1, and
IL-6, was investigated in four groups of MRC-5 cells.
The first group was composed of extract-untreated and
HSV-1-non-infected MRC-5 cells (the control cells); the
second group was composed of HSV-1-infected cells
without extract treatment (infected cells); the third
group was composed of extract-treated cells without
HSV-1 infection (treated cells); and the fourth group
was composed of extract-pretreated and HSV-1-infected
cells (treated-infected cells). A number of 3 × 104 cell/well
of MRC-5 cells were grown in RPMI-1640 cutlure
medium in 96-well flat-bottom tissue culture plates in a
humidified 5 % CO2 atmosphere for 24 h at 37 °C. For the
infected, treated, and treated-infected groups, the proce-
dures used were the same to that described in section
(3.2.9.2) for prophylaxis of MRC-5 cells against HSV-1
using the extracts’ IC50 values of IVR protocols which are
12.72 mg/ml. MBS extract was incubated in triplicates
with MRC-5 cells for the optimal time found earlier,
namely 1 h. The final volume of wells was 200 μl/well. A
triplicate of negative control wells contained cells with
RPMI-1640 maintenance medium only with final volume
of 200 μl/well. Afterwards, the supernatants from all the
wells were removed and centrifuged at 1000 g for 10 min
to be ready for the ELISA technique [80].
Sandwich Enzyme-Linked Immunosorbent Assay (ELISA)
The concentration of antiviral cytokines in the super-
natant of culture medium of MRC-5 cells was determined
by sandwich ELISA. MRC-5 cell line was chosen because
MRC-5 cells are human cells able to produce many
human cytokines including the antiviral cytokines, TNFα,
IFNβ, IL-1, and IL-6. On the other hand, Vero cell line
which was used in the antiviral assays done earlier on
RSV, was not used in measuring the antiviral cytokines
because Vero cells are not of human origin and IFNβ-
deficient cells.
The measurement of human TNFα using immuno-
metric assay (EIA) kits (Cayman, USA) was done accord-
ing to the kit’s instructions. In order to prepare the
standard curve, the standard of TNFα was reconstituted
in EIA buffer. The standard dilutions must be present in
the same biological fluid “matrix” as that of the sample to
accurately assay unpurified samples. The standard was
diluted in the sample matrix (the IC50 of MBS extract in
RPMI-1640 culture medium) excluded from the target
cytokine, TNFα. The standard dilutions, in triplicates,
were prepared as 2-fold serial dilutions ranged from 250
to 3.9 pg/ml in eight tubes of 15 ml capacity (Orange Sci-
entific, Europe); the 8th tube containing only the sample
matrix with zero concentration of the standard. One hun-
dred microliters of the standard or the samples were
added to the microtiter plate which was supplied with the
kit. The microtiter plate was already coated with mono-
clonal antibodies specific for TNFα. The samples were
assayed in triplicates. One hundred microliters of Acetyl-
cholinesterase: TNFα Fab’ conjugate were added to the
wells of the standards and the samples. The plates were
covered with plastic films and incubated overnight at 4 °C.
The quantification of the conjugate was achieved by meas-
uring its acetylcholinesterase activity with freshly prepared
Ellman’s reagent (acetylcholine and 5,5’-dithio-bis-(2-
nitrobenzoic acid). All of the wells were rinsed 5–6 times
with washing buffer after removing their contents. Two
hundred microliters of Ellman’s reagent were added to all
of the wells. The plate was covered with plastic film and
incubated for six hours at 25 °C in shaker incubator. Blank
wells contained only Ellman’s reagent added to the tripli-
cate wells of the 8th standard (to subtract the color effect).
Later, the absorbance (OD) was measured at 412 nm
(reference 690 nm) using a 96-well plate ELISA reader.
The samples’ concentrations were determined by extrapo-
lating OD values of TNFα to the generated linear standard
curve (the average absorbance on the vertical axis versus
the corresponding standard concentration on the horizon-
tal axis).
For the measurement of the concentration of IFNβ,
IL-1, and IL-6 in the supernatant of MRC-5 cell culture
medium, an ELISA kit from (abcam, USA) was used.
IFNβ, IL-1, and IL-6 standards were freshly prepared by
reconstituting in the standard diluent buffer to give a
stock concentration of 400 pg/ml. Two hundred microli-
ters of this stock was added in triplicate to the already
coated microtiter plates provided by the kit. Each plate
was coated with monoclonal IFNβ, IL-1, or IL-6 specific
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antibodies. From stock wells serial 2-fold dilutions, in
triplicates, of IFNβ, IL-1, and IL-6 standards were pre-
pared by diluting the standard in the sample matrix
which composed of the IC50 of MBS extract in RPMI-
1640 medium, excluded from the target cytokines. IFNβ,
IL-1, and IL-6 standards’ concentrations ranged from
400 to 12.5 pg/ml; and the last standard contained zero
concentration of IFNβ, IL-1, and IL-6 standards in
sample matrix. The prepared samples (100 μl/well) were
added, in triplicates. Then, 50 μl of freshly prepared
biotinylated anti- IFNβ, IL-1, or IL-6 antibodies, diluted
in biotinylated antibody diluents, were added to all of
the wells. The plates were covered with plastic films and
incubated two hours at 25 °C. Later, all the wells’
contents were removed and the wells were washed for
two times with washing buffer. One hundred microliter
of freshly prepared Streptavidin-horse radish peroxidase
(Streptavidin-HP), diluted in HP diluent, were added to
all wells. The plates were covered and incubated for
30 min at 25 °C. Two washes with washing buffer were
done to rinse all the wells. One hundred microliters of
freshly prepared substrate solution; chromogen TMB
(5-thio-2-nitrobenzoic acid) were added to the wells
and incubated in dark for 20 min. The reaction was
terminated by adding H2SO4, a stopping reagent. The
blanks, in triplicates, were composed of the substrate
chromogen solution along with the stopping reagent
added to the zero standard wells. A colored product
was formed in proportion to the level of IFNβ, IL-1,
and IL-6 cytokines in the tested supernatants. The ab-
sorbance was measured at 450 nm (reference 620 nm) by
ELISA reader. The samples’ concentrations were deter-
mined by extrapolating OD values of IFNβ, IL-1, or IL-6
samples to the generated linear standard curve.
Data analysis
Data are presented as mean ± 2SE from three independ-
ent experiments. The selectivity index (SI) was deter-
mined by the ratio of CC50 to IC50. The effect of the
tested MBS extract on the inhibition of viral replication
was evaluated by SPSS software version (12.0.0.2). The
statistically different effects of the extract on the inhib-
ition of RSV or HSV-1 replication were compared with
the control groups using the Student’s t-test. Differences
were considered significant at P <0.05.
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